Abstract:546 Background: Clinical trials are integral to science and can ensure access to standard of care treatments, providing benefits to individual participants and society. Unfortunately, fewer than 5% of eligible cancer patients participate in clinical trials, and large facets of the population remain starkly underrepresented, excluding them from these benefits and potentially compromising the generalizability of biomedical knowledge. Adverse social determinants of health (SDOH), or social vulnerability, may affect awareness and the decision to participate in a clinical trial, especially in underrepresented or historically excluded populations. In this study, we evaluate the association between population-level SDOH and clinical trials awareness and participation. Methods: We performed a cross-sectional analysis of the 2021 Health Information National Trends – Surveillance, Epidemiology, and End Results (HINTS-SEER), a nationally representative survey of 1,234 cancer survivors. The primary outcomes of interest included awareness of clinical trials “as a possible treatment option for your cancer” and “participation in a clinical trial for treatment of your cancer”. The primary exposure was the Centers for Disease Control and Prevention Social Vulnerability Index (CDC SVI), which was linked to each survey respondent by ZIP code of residence. Survey weighted multivariable logistic regression analyses were performed to evaluate the association between SVI quintile and clinical trial awareness and participation, adjusting for age, sex, race/ethnicity, and education level. Results: This survey weighted analysis represents a population of over 400,000 patients. Only 15.1% of patients were aware of clinical trials, with the most socially vulnerable patients having lower rates of awareness compared to the least socially vulnerable patients (8.5% vs. 17.9%). Similarly, only 7.7% of patients participated in a clinical trial, with the most socially vulnerable patients having lower rates of participation compared to the least socially vulnerable patients (3.0% vs. 10.1%). On multivariable analysis, the most socially vulnerable patients had significantly lower odds of clinical trials awareness (OR 0.43, CI 0.20 – 0.94) and clinical trials participation (OR 0.15, CI 0.03 – 0.73) compared to the least socially vulnerable patients, adjusting for age, sex, race/ethnicity, and education level. Conclusions: In this analysis of HINTS-SEER, a contemporary and novel survey of cancer survivors, rates of clinical trial awareness and participation remain concerningly low. Notably, adverse SDOH has a strong influence, with the most vulnerable patients being far less likely to be aware of or participate in a clinical trial. With the goal of achieving equitable cancer care, identifying and alleviating barriers to clinical trial participation, especially those rooted in SDOH, is critical.

The association between social vulnerability and clinical trials awareness and participation: A HINTS-SEER analysis.